{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval has not yet been reached.","groupId":"OG000","lowerLimit":"7.0","upperLimit":"NA","value":"17.1"},{"comment":"The upper bound of the 95% confidence interval has not yet been reached.","groupId":"OG001","lowerLimit":"9.7","upperLimit":"NA","value":"16.6"},{"comment":"The upper bound of the 95% confidence interval has not yet been reached.","groupId":"OG002","lowerLimit":"11.5","upperLimit":"NA","value":"35.4"},{"groupId":"OG003","lowerLimit":"12.1","upperLimit":"47.6","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"Overall survival time is defined as the time from registration to death due to any cause. The median and 95% confidence intervals will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lymphoma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II (Lymphoma Patients Receiving 20 mg LBL589)"},{"description":"Myeloma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II (Myeloma Patients Receiving 20 mg LBH589)"},{"description":"Lymphoma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Phase II (Lymphoma Patients Receiving 30/40 mg LBH589)"},{"description":"Myeloma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Phase II (Myeloma Patients Receiving 30/40 mg LBH589)"}],"paramType":"MEDIAN","populationDescription":"Patients who were enrolled in and completed Phase II and treated at a starting dose of 20 mg or 30/40 mg LBH589 were evaluated in this analysis.","reportingStatus":"POSTED","timeFrame":"Time from registration to death due to any cause, assessed up to 2 years post-treatment","title":"Overall Survival Time (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}